
Paul Kavanagh, partner at law firm Dechert, explores the relationship between GDPR and CTR, and its potential impact on the …

New research from the University of East Anglia (UEA) has argued that general practitioners (GPs) in the UK are lacking …

The number of Americans infected with Hepatitis A has increased 300% in the past three years, according to figures from …

Deaths from heart disease among people under the age of 75 have increased for the first time in 50 years. …

Eli Lilly’s vascular endothelial growth factor (VEGF) receptor 2 antagonist Cyramza (ramucirumab) has received approval in the US as a …

Forty-four US States have filed a lawsuit against 20 generic drugmakers – including Teva Pharmaceuticals – over allegations the firms …

The FDA has revealed that it plans to terminate its “alternative summary reporting” programme which has allowed the manufacturers of …

This week was a particularly bad one for the NHS after it was revealed thousands of EU nurses were leaving …

A long-acting, injectable HIV drug combo is to be tested in a clinical trial of 350 volunteers with HIV. The …

Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) has hit a hurdle, failing its primary endpoint in a Phase 3 trial investigating …

Gilead Sciences has agreed to donate 11 years’ worth PrEP drugs for up to 200,000 individuals each year, following “discussions …

NICE has announced its final appraisal decision on Genentech’s Ocrevus (ocrelizumab), choosing to recommend the drug for use on the …

Nearly 5,000 EU nurses and midwifes have left the NHS over the past two years. The number of EU nationals …

Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss firm Novartis in a deal …

Sanofi has revealed that its interleukin-4 and interleukin-13 (IL-4 and IL-13) inhibitor Dupixent (dupilumab) has been awarded marketing approval by …

Patients taking some newer diabetes medications – SGLT2 inhibitors – have been warned that they may be at risk of …

Pfizer’s Lorviqua (lorlatinib), or Lorbrena as it is known in the US, Canada and Japan, has just been awarded conditional …

Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the …

AstraZeneca has unveiled new Phase 3 data on the efficacy of its Bruton tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) in …

Brand name prescription drugs cost on average 4.3 times more in the United States than in the UK, according to …